Article Cited by others


Macitentan: An important addition to the treatment of pulmonary arterial hypertension

Khadka Anjan, Singh Brashier Dick B, Tejus Anantharamu, Sharma Ashok Kumar

Year : 2015| Volume: 6| Issue : 1 | Page no: 53-57

   This article has been cited by
1 A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension
Martin Bedan,Daniela Grimm,Markus Wehland,Ulf Simonsen,Manfred Infanger,Marcus Krüger
Basic & Clinical Pharmacology & Toxicology. 2018;
[Pubmed]  [Google Scholar] [DOI]
2 A Novel Synthesis of Macitentan, an Endothelin Receptor Antagonist
Majid Nami,Sara Nasiri Sovari,Yaghoub Haghighatnia,Minoo Dabiri,Peyman Salehi
Organic Preparations and Procedures International. 2017; 49(3): 258
[Pubmed]  [Google Scholar] [DOI]
3 The use of Macitentan in Fontan circulation: a case report
Polyvios Demetriades,Amir Aziz,Robin Condliffe,Sarah E. Bowater,Paul F. Clift
BMC Cardiovascular Disorders. 2017; 17(1)
[Pubmed]  [Google Scholar] [DOI]
4 Macitentan in daily clinical practice: A single centre, 1-year experience
S. Cadenas-Menéndez,P. Álvarez-Vega,J. Martín-Moreiras,M. Barreiro-Pérez,M.Á. Gómez-Sánchez,P.L. Sánchez-Fernández
Revista Portuguesa de Pneumologia (English Edition). 2017;
[Pubmed]  [Google Scholar] [DOI]
5 Association therapy with macitentan added to sildenafil in a thalassemic patient with pulmonary hypertension
Michele Correale,Stefano Zicchino,Ilenia Monaco,Natale Daniele Brunetti,Matteo Di Biase
International Journal of Cardiology. 2016;
[Pubmed]  [Google Scholar] [DOI]
6 A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment
Robert S. Kerbel
The Cancer Journal. 2015; 21(4): 274
[Pubmed]  [Google Scholar] [DOI]


Read this article